The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

Leukemia

Volumn 26, Issue 2, 2012, Pages 255-264

  De Vries, J F ^a   Zwaan, C M ^b   De Bie, M ^a   Voerman, J S A ^a   Den Boer, M L ^b   Van Dongen, J J M ^a   Van Der Velden, V H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

acute lymphoblastic leukemia; calicheamicin; CD22; CMC 544 (inotuzumab ozogamicin); immunoconjugate; pediatric

Indexed keywords

CALICHEAMICIN; CD22 ANTIGEN; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CHILDHOOD LEUKEMIA; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84856710962     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.206     Document Type: Article

References (41)

1. Johnston WT, Lightfoot TJ, Simpson J, Roman E. Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol 2010; 34: 659-666.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178. (Pubitemid 43076714)
3. Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2010; 24: 1-18.
4. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
5. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33 (Suppl 8): S2-S7.
6. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006; 33 (Suppl 8): S8-S14.
7. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13: 47-58. (Pubitemid 34119634)
8. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254. (Pubitemid 32591442)
9. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198-1201.
10. Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol 2008; 148: 768-776.
11. DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 2005; 54: 11-24. (Pubitemid 40064481)
12. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103: 1807-1814. (Pubitemid 38268977)
13. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocytespecific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 15: 481-504. (Pubitemid 27169290)
14. Cesano A, Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol 2003; 30: 253-257. (Pubitemid 36506320)
15. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007; 21: 2240-2245. (Pubitemid 350011695)
16. DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004; 10: 8620-8629. (Pubitemid 40053430)
17. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28: 2085-2093.
18. van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004; 18: 983-988. (Pubitemid 38714624)
19. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
20. Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003; 17: 468-470. (Pubitemid 36277623)
21. Gudowius S, Recker K, Laws HJ, Dirksen U, Troger A, Wieczorek U et al. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Padiatr 2006; 218: 327-333. (Pubitemid 44862391)
22. de Vries JF, von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Willemze R, Falkenburg JH et al. Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing. Haematologica 2007; 92: 1671-1678. (Pubitemid 350248247)
23. de Vries JF, Falkenburg JH, Willemze R, Barge RM. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 2006; 91: 912-919. (Pubitemid 44023144)
24. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolonevincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268. (Pubitemid 46606259)
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868. (Pubitemid 28124064)
26. van der Burg M, van Veelen LR, Verkaik NS, Wiegant WW, Hartwig NG, Barendregt BH et al. A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation. J Clin Invest 2006; 116: 137-145. (Pubitemid 43121798)
27. Freundt EC, Czapiga M, Lenardo MJ. Photoconversion of Lysotracker Red to a green fluorescent molecule. Cell Research 2007; 17: 956-958. (Pubitemid 350126866)
28. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987; 84: 3004-3008. (Pubitemid 17064766)
29. Zaman GJ, Versantvoort CH, Smit JJ, Eijdems EW, de Haas M, Smith AJ et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Research 1993; 53: 1747-1750. (Pubitemid 23127097)
30. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109: 4168-4170. (Pubitemid 46743379)
31. Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 2009; 146: 34-43.
32. Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippe J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 2006; 42: 295-309. (Pubitemid 43132884)
33. Den Boer ML, Pieters R, Kazemier KM, Janka-Schaub GE, Henze G, Veerman AJ. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 2023-2030.
34. den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092-2098. (Pubitemid 28185513)
35. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R et al. Internalization and cell cycledependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004; 18: 316-325. (Pubitemid 38240048)
36. Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia 2006; 20: 2093-2101. (Pubitemid 44782834)
37. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115: 5191-5201.
38. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005; 105: 1295-1302. (Pubitemid 40170906)
39. Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hahlen K et al. Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia 2008; 22: 2284-2285.
40. ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007; 21: 248-252. (Pubitemid 46158116)
41. Brethon B, Yakouben K, Oudot C, Boutard P, Bruno B, Jerome C et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol 2008; 143: 541-547.